Light-Chain Multiple Myeloma: A Diagnostic Challenge
Open Access
- 29 October 2021
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 13 (10)
Abstract
Light-chain multiple myeloma (LCMM) is a less frequent type of multiple myeloma (MM), with a more aggressive course and poorer prognosis. It is characterized by the inability of the malignant plasma cells to produce heavy chains, resulting in the exclusive production of light chains. Therefore, no M-spike is visible in serum protein electrophoresis. We described the case of a 67-year-old female who presents to the emergency department with anemia, severe renal insufficiency, and multiple lytic bone lesions. After three days, the diagnosis of kappa light chain multiple myeloma was made in a patient with elevated serum and urinary kappa light chains and a bone marrow aspirate with 21.7% of atypical plasma cells. The rapid diagnosis allowed prompt referral to a specialized multiple myeloma center and early initiation of treatment.Keywords
This publication has 9 references indexed in Scilit:
- Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†Annals of Oncology, 2021
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2020
- An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease MonitoringCureus, 2018
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentJournal of Clinical Oncology, 2016
- Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myelomaLeukemia, 2015
- Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term studyWorld Journal of Surgical Oncology, 2014
- The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal ImpairmentPLOS ONE, 2014
- Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agentsAnnals of Oncology, 2014